A DNA methylation prognostic signature of glioblastoma: Identification of NPTX2-PTEN-NF-κB nexus

Cancer Research

Volumn 73, Issue 22, 2013, Pages 6563-6573

  Shukla, Sudhanshu ^a   Patric, Irene Rosita Pia ^a   Thinagararjan, Sivaarumugam ^a   Srinivasan, Sujaya ^a   Mondal, Baisakhi ^a   Hegde, Alangar S ^b   Chandramouli, Bangalore A ^c   Santosh, Vani ^c   Arivazhagan, Arimappamagan ^c   Somasundaram, Kumaravel ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b SRI SATHYA SAI INSTITUTE OF HIGHER MEDICAL SCIENCES   (India)

^c NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; TEMOZOLOMIDE;

ANCHORAGE INDEPENDENT GROWTH; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DRUG SENSITIVITY; GLIOBLASTOMA; GLIOMA CELL; GROWTH INHIBITION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MARKER GENE; NEURAL PENTRAXIN 2 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; SURVIVAL PREDICTION;

ANIMALS; BRAIN NEOPLASMS; C-REACTIVE PROTEIN; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICROARRAY ANALYSIS; NERVE TISSUE PROTEINS; NF-KAPPA B; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RATS; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84888351457     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0298     Document Type: Article

References (38)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
2. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710. (Pubitemid 350070717)
3. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006;65:1181-8. (Pubitemid 44885942)
4. Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol 2009;19:188-97.
5. Reddy SP, Britto R, Vinnakota K, Aparna H, Sreepathi HK, Thota B, et al. Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. Clin Cancer Res 2008;14:2978-87.
6. Santosh V, Arivazhagan A, Sreekanthreddy P, Srinivasan H, Thota B, Srividya MR, et al. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev 2010;19:1399-408.
7. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, et al. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 2010;19:1409-22.
8. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510-22.
9. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
10. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004;64:6503-10. (Pubitemid 39297907)
11. Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003;63:6613-25. (Pubitemid 37322939)
12. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-7. (Pubitemid 36373650)
13. Rao SA, Santosh V, Somasundaram K. Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 2010;23:1404-17.
14. Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011;6:e17438.
15. Reif K NC, Thomas G, Hall A, Cantrell DA. Phosphatidylinositol 3-kinase signals activate a selective subset of Rac/Rho-dependent effector pathways. Curr Biol 1996;6:1445-55. (Pubitemid 27012243)
16. Suvasini R SK. Essential role of PI3-kinase pathway in p53-mediated transcription: implications in cancer chemotherapy. Oncogene 2010;29:3605-18.
17. Das S, El-Deiry WS, Somasundaram K. Regulation of the p53 homolog p73 by adenoviral oncogene E1A. J Biol Chem 2003;278:18313-20. (Pubitemid 36799451)
18. Pahl H. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-66.
19. von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, et al. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res 2005;33:D433-7. (Pubitemid 40207910)
20. Hooper SD, Bork P. Medusa: a simple tool for interaction graph analysis. Bioinformatics 2005;21:4432-3. (Pubitemid 41782941)
21. Castro MA, Filho JL, Dalmolin RJ, Sinigaglia M, Moreira JC, Mombach JC, et al. ViaComplex: software for landscape analysis of gene expression networks in genomic context. Bioinformatics 2009;25:1468-9.
22. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. Amultigene predictor of outcome in glioblastoma. Neuro Oncol 2009;12:49-57.
23. van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res 2011;17:1-8.
24. Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NF-κB pathway: a therapeutic target in glioblastoma. Oncotarget 2011;2:646-53.
25. Institute NC. REMBRANDT home page. Available at 〈http://rembrandt. nci.nih.gov〉. Accessed 2011 February 17, 2005.
26. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73. (Pubitemid 43357943)
27. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-96. (Pubitemid 32843830)
28. Zanotto-Filho A, Braganhol E, Schroder R, de Souza LH, Dalmolin RJ, Pasquali MA, et al. NF-κB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 2010;81:412-24.
29. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005;4:217-20. (Pubitemid 41365319)
30. Liu Q, Li G, Li R, Shen J, He Q, Deng L, et al. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol 2010;100:165-76.
31. Roland CL, Harken AH, Sarr MG, Barnett CC Jr. ICAM-1 expression determines malignant potential of cancer. Surgery 2007;141:705-7. (Pubitemid 46863445)
32. Schroder C, Witzel I, Muller V, Krenkel S, Wirtz RM, Janicke F, et al. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol 2011;137:1193-201.
33. Zhang L, Gao J, Li L, Li Z, Du Y, Gong Y. The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro. Mol Biol Rep 2010;38:4903-11.
34. Moran LB, Hickey L, Michael GJ, Derkacs M, Christian LM, Kalaitzakis ME, et al. Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies. Acta Neuropathol 2008;115:471-8.
35. Stambolic V MD, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. Regulation of PTEN transcription by p53. Mol Cell Biol 2001;153:1369-80.
36. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012;13:283-96.
37. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-5.
38. Romashkova JA, Makarov SS. NF-κB is a target of AKT in antiapoptotic PDGF signalling. Nature 1999;401:86-90.